Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo ...

The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

The United Laboratories International Holdings Limited and Novo Nordisk (NVO) announced earlier that Novo Nordisk and TUL’s wholly-owned ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Co., Ltd. have entered into an exclusive license agreement for UBT251 for the treatment of obesity, type 2 diabetes, and other diseases.

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

The United Laboratories, Novo Nordisk ink exclusive global license agreement for UBT251: Guangdong, China Wednesday, March 26, 2025, 10:00 Hrs [IST] The United Laboratories Intern ...